tumor cell therapy Articles
-
Effect of interferon receptor pathway on CAR-T cell-mediated killing of solid tumors
Researchers at Massachusetts General Hospital (MGH) have found that interferon gamma receptor (IFNgR) signaling is essential for the susceptibility of CAR-T cell immunotherapy to kill malignant gliomas. The same phenomenon has been observed in other solid tumors. The findings may partially explain why liquid and solid tumors respond very differently to CAR-T cell therapy. Chimeric antigen ...
-
Absorbed dose using a nanoscale ion beam for Bragg peak calibrations
The proton beam was investigated for cancer cell therapy in the pancreas. Neon ion interaction profiles were compared with the result of the proton beam, which was investigated for nanoscale ion beam interactions. Simulation for the Bragg peak calculation was performed for interactions with a human organ, the pancreas. The results show the absorbed dose and dose equivalent, which vary with the ...
-
Synthesis and characterisation of new designed protoporphyrin-stabilised gold nanoparticles for cancer cells nanotechnology-based targeting
Nanotechnology has entered the field of medicine in recent dacades and especially, in drug delivery systems, nanoparticles have shown an ability to improve pharmacokinetics, pharmacodynamics, efficacy and to reduce the toxicity of associated drugs. In this study, we have designed a new protoporphyrin-conjugated gold nanoparticle to selectively target and photo- or sonodynamic therapy of tumoural ...
-
New Cell Contenders in the CAR Field (Part 2)
Why do we need new cell contenders in the CAR field? Well, different CAR immune cells have different advantages and sometimes unique challenges or limitations. So, we began our discussion of alternative CAR-cell types with CAR-NK cells due to their current standing as the most popular alternative CAR-based therapy. However, the expansion of CARs to other cell types has already begun and ...
By Indee Labs
-
Four Novel Drug Delivery Systems You Should Know
In the field of medicine, effectively delivering drugs to the target site in the body is crucial for successful treatment. Over the years, several innovative drug delivery systems have been developed to improve drug efficacy and patient outcomes. In this article, we will discuss four novel drug delivery systems that have shown promising results in recent research. These systems include ...
-
Preventive cancer vaccine based on neoantigens gets put to the test
Studying the vaccine in dogs could provide insight into its effectiveness in people What if someone told you that a vaccine shot could prevent you from getting multiple types of cancer—ones as different from each other as breast cancer and lymphoma? Stephen A. Johnston, cofounder of the health-care start-up Calviri and a scientist at Arizona State University’s Biodesign Institute, ...
By Calviri
-
Natural Killer Cells May Be Scaled and Engineered as a Next Generation, Off-the-Shelf Cell Therapy for Cancer
The advent of immunotherapies for cancer, and more recently of cellular immunotherapies, has substantially altered the treatment landscape. In hematological malignancies, complete response rates to CAR-T cells can exceed 80%. These responses are often durable in nature and have attracted considerable excitement and investment in the development of cell therapies for an expanded range of ...
By Nkarta, Inc.
-
Tumor Glycan-Targeted Therapy
Glycosylation is a sophisticated type of post-translational modification that impacts over 50% of cellular proteins and is a critical regulator of many eukaryotic processes. Aberrant glycosylation is a common hallmark of many malignancies and is important at all stages of tumor growth. Glycosylation regulates a range of physiopathological processes, including cell-cell adhesion, cell-matrix ...
-
A Novel Potential Target for CAR-T Cell Therapy in Human Solid Tumors Discovered
At present, chimeric antigen receptor T cell therapy (CAR-T) has made significant achievements in the treatment of specific hematological cancers, allowing patients with relapsed/refractory disease to survive longer and become healthier, but in clinical studies, cell therapy has actually not been successful in the treatment of patients with solid tumors, in part due to the lack of tumor targets ...
-
Cytokines in CAR-T Cell Therapy
What is CAR T-cell therapy? Car-t cell therapy involves genetically engineering T cells isolated from patients or allogeneic donors to express chimeric antigen receptors (CAR) that specifically recognize and kill tumor cells. As a "living" drug, CAR-T therapy is very different from traditional drugs. It is a new type of precision targeted therapy for the treatment of tumors. Compared with ...
-
The ins and outs of TCR-T cell therapy
Adoptive cell transfer (ACT) therapy is one of the most effective therapeutic options for tumor immunotherapy that is currently emerging in clusters. Chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs) are the main adoptive immunotherapies in recent years. TCR-engineered T cells express tumor antigen-specific receptors with alpha and beta chains generated from high-quality, ...
-
CAR-T Cell Anti-Cancer Therapy Ushered in A Revolutionary Breakthrough!
Chimeric antigen receptor T cells (CAR-T) and T cell antigen receptor chimeric T cells (TCR-T) are currently the "top stream" in adoptive T cell tumor immunotherapy. In particular, CAR-T therapy, which has been approved by the FDA, is rewriting the treatment paradigm of some hematological tumors. However, adoptive T cell therapy remains of little success in solid tumors. The main reason is that ...
-
A Plant Immune Protein May be Expected to Completely Cure Cancer!
Cancer, caused by abnormal cell proliferation, is one of the world's major public health problems. Recently, in a research report entitled "A plant immune protein enables broad antitumor response by rescuing microRNA deficiency" published in Cell, Scientists from institutions such as Peking University have found that a special plant immune protein may achieve a broad spectrum of anti-tumor ...
-
Discovery of Bispecific Antibodies and Immune Checkpoint Inhibitors That Kill Glioblastoma Cells and Melanoma Cells, and Block the Metastasis of Malignant Melanoma Cells to the Lung by Over 90%
Ocean Biomedical will be a wholly owned subsidiary of Aesther Healthcare Acquisition Corp. and will change its name to Ocean Biomedical, Inc., expected to be listed on NASDAQ under the symbol, “OCEA”. PROVIDENCE, R.I. and NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Ocean Biomedical and Aesther Healthcare Acquisition Corp. (“Aesther”) (NASDAQ: AEHA) ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you